The FDA lifts a par­tial hold on Mer­sana's top drug -- and then its shares crater

Mer­sana $MRSN and the FDA have come up with a new­ly re­vised de­vel­op­ment pro­gram for the biotech’s lead drug just a cou­ple months af­ter a pa­tient’s death trig­gered a par­tial hold on en­rolling more peo­ple for the study.

From the be­gin­ning, Mer­sana not­ed that the death may have been caused by XMT-1522, an an­ti­body drug con­ju­gate de­signed to drop a ther­a­peu­tic pay­load on HER2-ex­press­ing tu­mors. 

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.